SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US None
App. No.: 18/774,801

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

This invention provides compounds that have spirocyclic E3 Ubiquitin Ligase targeting moieties (Degrons), which can be used as is or linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.

Claims (55)

1 . A compound of Formula I:

or a pharmaceutically acceptable salt thereof;

wherein:

W 1 is C═O;

W 2 is C═O;

X is NH;

n is 0, 1, 2, or 3;

is a single or double bond;

Y and Z are each independently selected from the group consisting of CH 2 , CHR 12 , C(R 12 ) 2 , C(O), N, NH, NR 13 , O, S, and S(O) as permitted by valency;

R 5 is selected at each instance from the group consisting of alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkoxy, azide, amino, cyano, aryl, heteroaryl, heterocycle, —NHalkyl, —N(alkyl) 2 , —NHSO 2 alkyl, —N(alkyl)SO 2 alkyl, —NHSO 2 aryl, —N(alkyl)SO 2 aryl, —NHSO 2 alkenyl, —N(alkyl)SO 2 alkenyl, —NHSO 2 alkynyl, —N(alkyl)SO 2 alkynyl, and haloalkyl;

or two R 5 substituents together with the carbon atom(s) to which they are bound form a 3, 4, 5, or 6 membered ring;

R 6 is a bond, wherein Y or Z is substituted with R 10 ;

or R 6 is a divalent moiety attached to Y and Z that contains 1 to 5 contiguous carbon atoms that form a 3 to 8-membered ring wherein 1, 2, or 3 carbon atoms can be replaced with a nitrogen, oxygen or sulfur atom, and wherein one of the ring atoms is substituted with R 10 and the others are optionally substituted with R 11 ;

wherein the contiguous atoms of R 6 can be attached through a single or double bond;

forms a bicyclic moiety which is substituted with R 10 and optionally substituted with one or more groups independently selected from the group consisting of R 11 and oxo;

R 10 is Linker-Targeting Ligand;

R 11 is selected at each instance from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, halogen, hydroxyl, amino, cyano, alkoxy, aryl, heteroaryl, heterocycle, carbocyclic, alkylamino, alkylhydroxyl, and haloalkyl;

R 12 is selected from the group consisting of alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkoxy, azide, amino, —C(O)H, —C(O)OH, —C(O)(alkyl), —C(O)O(alkyl), —NH(alkyl), —N(alkyl) 2 , —NHSO 2 alkyl, —N(alkyl)SO 2 alkyl, —NHSO 2 aryl, —N(alkyl)SO 2 aryl, —NHSO 2 alkenyl, —N(alkyl)SO 2 alkenyl, —NHSO 2 alkynyl, —N(alkyl)SO 2 alkynyl, aryl, heteroaryl, heterocycle, carbocyclic, cyano, nitro, nitroso, —SH, —S-alkyl, and haloalkyl;

R 13 is selected from the group consisting of alkyl, alkenyl, alkynyl, —C(O)H, —C(O)OH, —C(O)(alkyl, aryl, heteroaryl, or heterocycle), —C(O)O(alkyl, aryl, heteroaryl, or heterocycle), aryl, heteroaryl, and heterocycle;

Linker is

X 1 and X 2 are independently selected from the group consisting of bond, NH, NR 25 , CH 2 , CHR 25 , C(R 25 ) 2 , O, and S;

R 20 , R 21 , R 22 , R 23 , and R 24 are independently selected from the group consisting of bond, alkyl, —C(O)—, —C(O)O—, —OC(O)—, —C(O)alkyl, —C(O)Oalkyl, —C(S)—, —SO 2 —, —S(O)—, —C(O)NH—, —NHC(O)—, —N(alkyl)C(O)—, —C(O)N(alkyl)-, —O—, —S—, —NH—, —N(alkyl)-, —CH(—O—R 26 )—, —CH(—NHR 25 )—, —CH(—NH 2 )—, —CH(—NR 25 2 )—, —C(—O—R 26 )alkyl-, —C(—NHR 21 )alkyl-, —C(—NH 2 )alkyl-, —C(—NR 25 2 )alkyl-, -alkyl(R 27 )-alkyl(R 28 )—, —CR 27 R 28 —, —P(O)(OR 26 )O—, —P(O)(OR 26 )—, —NHC(O)NH—, —N(R 25 )C(O)N(R 25 )—, —N(H)C(O)N(R 25 )—, alkenyl, haloalkyl, alkoxy, alkynyl, aryl, heterocycle, heteroaryl, lactic acid, and glycolic acid;

R 25 is selected at each instance from the group consisting of alkyl, —C(O)H, —C(O)OH, —C(O)alkyl, —C(O)Oalkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocycle;

R 26 is hydrogen, alkyl, silane, arylalkyl, heteroarylalkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocycle; and

R 27 and R 28 are independently selected from the group consisting of hydrogen, alkyl, and amine;

or R 27 and R 28 together with the carbon atom to which they are attached, form C(O), C(S), C═CH 2 , a C 3 -C 6 spirocarbocycle, or a 4-, 5-, or 6-membered spiroheterocycle comprising 1 or 2 heteroatoms selected from the group consisting of N and O;

Targeting Ligand is a small molecule means for binding a Targeted Protein that mediates a disease; and

Targeted Protein is selected from the group consisting of 4BVV, ABL1, ABL2, AKT1, AKT2, androgen receptor, AP1, AP2, ASH1L, ATAD2, ATF2, AXL, BAZ2A, BAZ2B, Bcl-2, Bcl-XL, BCR-ABL, BMX, BRPF1, cathepsin, CECR2, CSF1R, cyclin dependent kinase, DDR1, dihydrofolate reductase, DOT1L, EED, EHMT1, EHMT2, EPHA2, EPHA3, EPHA4, EPHA7, EPHB4, estrogen receptor, EZH2, factor Xa, fatty acid binding protein, FES, FKBP, FLAP, FLT3, FYN, GSG2, HBV, HCK, HCV protease, HDM2, heat shock protein, histone acetyltransferase, HIV integrase, HIV protease, HIV reverse transcriptase, IDO1, IDH1, IGF1R, INSR, ITK, kallikrein 7, KDM4, KDM5, KDM6, KIT, kringle domain V, KSR1, L3MBTL3, lactoylglutathione lyase, LCK, LSD1, LYN, lysine methyltransferase, lysine-specific histone demethylase, mast/stem cell growth factor receptor, MCL-1, MDM2, MDM4, MEK1, MEN1, MER, MERTK, MET, mPGES-1, MST1R, MTH1, NTRK, PAK1, PAK4, PB1, PDGFR receptor, PDZ, PHIP, phospholipase A2 domain, PNET, PPAR-gamma, protein S100-A7, RAML receptor, RCC receptor, ROS1 receptor, saposin-B, Sec7, SEGA receptor, SETD2, SETD7, SETD8, SETDB1, SF6D, SH2 domain, SMYD2, SMYD3, SUV4-20H1, TAF1, TAF1L, TANK1, TEC, tie 2 receptor, TNIK, mTORC1, mTORC2, TRKB, TRIM24, U09-CX-5279, VEGF receptor, and YES.

2 . The compound of claim 1 , wherein n is 0.

3 . The compound of claim 1 , wherein R 6 is a divalent moiety attached to Y and Z that contains 1 to 5 contiguous carbon atoms that form a 3 to 8-membered ring wherein 1, 2, or 3 carbon atoms can be replaced with a nitrogen, oxygen or sulfur atom wherein one of the ring atoms is substituted with R 10 and the others are optionally substituted with R 11 ; wherein the contiguous atoms of R 6 can be attached through a single or double bond.

4 . The compound of claim 1 , wherein

forms a bicyclic moiety which is substituted with R 10 and optionally substituted with one or more groups independently selected from R 11 and oxo.

5 . The compound of claim 4 , wherein

is selected from the group consisting of:

6 . The compound of claim 1 , wherein the compound is selected from the group consisting of: